1-3 of 3
Kenneth Lau, BA
Close
Sort by
Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD, Thomas G. Martin, MD, Melissa Alsina, MD, Kenneth H. Shain, MD PhD, Hearn J. Cho, MD PhD, Jeffrey L Wolf, MD, Anuj Mahindra, MD, Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2014) 124 (21): 303.
https://doi.org/10.1182/blood.V124.21.303.303
Published: 2014
Journal Articles

A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Myo Htut, MD, Jeffrey Zonder, M.D., Joseph W. Fay, MD, Andrzej J Jakubowiak, MD, PhD, Beverly Harrison, Kenneth Lau, BA, Brandi Hilder, Ann Ptaszynski, Selena A Rush, BS, Jonathan L. Kaufman, MD, Steven Michael Burt
Journal: Blood
Blood (2013) 122 (21): 1938.
https://doi.org/10.1182/blood.V122.21.1938.1938
Published: 2013
Journal Articles

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

Rachid Baz, MD, Thomas G Martin, III, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel Sullivan, M.D., Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Hui-Yi Lin, PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2013) 122 (21): 3200.
https://doi.org/10.1182/blood.V122.21.3200.3200
Published: 2013